<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Management of diabetes mellitus.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Michigan Quality Improvement Consortium. Management of diabetes mellitus. Southfield (MI): Michigan Quality Improvement Consortium; 2013 Mar. 1 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Michigan Quality Improvement Consortium. Management of diabetes mellitus. Southfield (MI): Michigan Quality Improvement Consortium; 2012 Jun. 1 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Cardiovascular disease, unspecified  (429.2); Complications affecting other specified body systems, not elsewhere classified, hypertension  (997.91); Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled  (250.01); Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled  (250.00); Eye examination, not otherwise specified  (95.09); General physical examination  (89.7)"/><FieldValue Value="MSH: Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors ; Antihypertensive Agents ; Blood Glucose Self-Monitoring ; Cardiovascular Diseases ; Counseling ; Dental Care ; Diabetes Mellitus ; Diabetes Mellitus, Type 1 ; Diabetes Mellitus, Type 2 ; Diabetic Diet ; Disease Management ; Glomerular Filtration Rate ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hypertension ; Hypolipidemic Agents ; Immunization ; Insulin ; Kidney Function Tests ; Liver Function Tests ; Patient Education as Topic ; Patient-Centered Care ; Physical Examination ; Platelet Aggregation Inhibitors ; Preconception Care ; Risk Factors ; Risk Reduction Behavior ; Self Care ; Smoking Cessation ; Thyroid Function Tests ; Tobacco Use Cessation Products ; Vaccination ; Vaccines "/><FieldValue Value="MTH: Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors ; Antihypertensive Agents ; Antilipemic agent ; Cardiovascular Diseases ; Cessation of smoking ; Counseling ; Creatinine measurement, serum (procedure) ; Dental Procedures ; Depression screen ; Diabetes Mellitus ; Diabetes Mellitus, Insulin-Dependent ; Diabetes Mellitus, Non-Insulin-Dependent ; Diabetic Diet ; Disease Management ; Glomerular Filtration Rate ; Hemoglobin A1c measurement ; Hemoglobin, Glycosylated ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hypertensive disease ; Hypolipidemic Agents ; Immunization ; Insulin ; Kidney Function Tests ; Liver Function Tests ; Measurement of serum lipid level ; Ophthalmic examination and evaluation ; Patient education (procedure) ; physical examination ; Platelet Aggregation Inhibitors ; risk factors ; Self-care interventions ; Thyroid Function Tests ; Thyroid stimulating hormone measurement ; Vaccination ; Vaccines "/><FieldValue Value="PDQ: insulin "/><FieldValue Value="SNOMEDCT_US: Angiotensin-converting enzyme inhibitor agent  (372733002); Angiotensin-converting enzyme inhibitor agent  (41549009); Antilipemic agent  (373267003); Antilipemic agent  (57952007); Assessment for risk of cardiovascular disease  (441829007); Counseling  (129441002); Counseling  (409063005); Creatinine measurement, serum  (113075003); Dental-oral procedure AND/OR service  (108306002); Dental-oral procedure AND/OR service  (225362009); Depression screening  (171207006); Diabetes clinical management plan  (412777005); Diabetes mellitus  (73211009); Diabetes self-management behavior  (405096004); Diabetic care education  (385805005); Diabetic diet  (160670007); Diet good  (226234005); Diet good  (310500000); Disorder of cardiovascular system  (49601007); Examination of foot  (284384005); Examination of retina  (274798009); Fasting lipid profile  (252150008); Foot care  (385955003); Glomerular filtration rate  (80274001); Glycosylated hemoglobin  (259689004); Hemoglobin A1c measurement  (43396009); HMG-CoA reductase inhibitor  (372912004); HMG-CoA reductase inhibitor  (96302009); Hypertensive disorder  (38341003); Hypotensive agent  (1182007); Hypotensive agent  (372586001); Immunization  (127785005); Insulin  (39487003); Insulin  (412222002); Insulin  (67866001); Liver function tests - general  (26958001); Liver function tests - general  (271552009); Measurement of serum lipid level  (271244005); Microalbumin measurement, urine, quantitative  (104819000); Ophthalmic examination and evaluation  (36228007); Patient education  (311401005); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Preconception care  (429070000); Referral to diabetes preconception counseling clinic  (415269004); Renal function study  (44277000); Risk factor  (80943009); Self-care interventions  (384758001); Self-monitoring of blood glucose  (308113006); Thyroid panel  (35650009); Thyroid stimulating hormone measurement  (61167004); Type 1 diabetes mellitus  (46635009); Type 2 diabetes mellitus  (44054006); Vaccine  (398827000); Vaccine  (71181003)"/><FieldValue Value="UMD: Analyzers, Laboratory, Blood, Glycated Hemoglobin  (17-109)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Type 1 and type 2 diabetes mellitus&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Endocrinology" /><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Nutrition" /><FieldValue Value="Ophthalmology" /><FieldValue Value="Podiatry" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Health Plans" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;To achieve significant, measurable improvements in the management of diabetes mellitus through the development and implementation of common evidence-based clinical practice guidelines&lt;/li&gt;&#xD;&#xA;&lt;li&gt;To design concise guidelines that are focused on key management components of diabetes mellitus to improve outcomes&lt;/li&gt;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients 18 to 75 years of age with type 1 or type 2 diabetes mellitus&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Evaluation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Periodic assessment&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Physical examination &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Cardiovascular risk factors &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Eye and foot exam &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Depression screen &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Laboratory tests&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Hemoglobin A1C &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Renal function (urinary microalbumin, serum creatinine, glomerular filtration rate [GFR]) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Fasting lipid profile &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Consider thyroid-stimulating hormone (TSH) test and liver function tests (LFTs) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management/Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Education, counseling, and risk factor modification&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Comprehensive, individualized diabetes self-management education (DSME) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Role of self-monitoring of blood glucose &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Cardiovascular risk reduction &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Self-care of feet &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Regular physical activity &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Smoking cessation and secondhand smoke avoidance &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Healthy diet &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Dental care &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Preconception counseling &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Medical treatment focused on smoking cessation, hypertension, lipids, and glycemic control&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Medications for tobacco dependence &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Antihypertensive therapy, including angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Statin therapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Antiplatelet therapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Individualized hemoglobin A1C goal &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Immunizations &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Michigan Quality Improvement Consortium (MQIC) health care analyst conducts a search of current literature in support of the guideline topic. Computer database searches are used to identify published studies, existing protocols and/or national guidelines on the selected topic developed by organizations such as the American Diabetes Association, American Heart Association, American Academy of Pediatrics, etc. If available, clinical practice guidelines from participating MQIC health plans and Michigan health systems are also used to develop a framework for the new guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For the current update of the guideline the American Diabetes Association database was searched in 2013. The specific search term used was ADA clinical practice recommendation 2013. No specific inclusion/exclusion criteria were applied.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Levels of Evidence for the Most Significant Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;ol start=&quot;1&quot; type=&quot;A&quot;&gt;&#xD;&#xA;&lt;li&gt;Randomized controlled trials&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Controlled trials, no randomization&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Observational studies&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Opinion of expert panel&lt;/li&gt;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Using information obtained from literature searches and available health plan guidelines on the designated topic, the Michigan Quality Improvement Consortium (MQIC) health care analyst prepares a draft guideline to be reviewed by the Medical Directors' Committee at one of their scheduled meetings. Priority is given to recommendations with [A] and [B] levels of evidence (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The initial draft guideline is reviewed, evaluated, and revised by the committee resulting in draft two of the guideline. Additionally, the Michigan Academy of Family Physicians participates in guideline development at the onset of the process and throughout the guideline development procedure. The MQIC guideline feedback form and draft two of the guideline are distributed to the medical directors, as well as the MQIC measurement and implementation group members, for review and comments. Feedback from members is collected by the MQIC health care analyst and prepared for review by the Medical Directors' Committee at their next scheduled meeting. The review, evaluation, and revision process with several iterations of the guideline may be repeated over several meetings before consensus is reached on a final draft guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;When consensus is reached on the final draft guideline, the medical directors approve the guideline for external distribution to practitioners with review and comments requested via the Michigan Quality Improvement Consortium (MQIC) health plans (health care analyst distributes final draft to Medical Directors' Committee, measurement and implementation groups to solicit feedback).&lt;/p&gt;&#xA;&lt;p&gt;The MQIC health care analyst also forwards the approved guideline draft to appropriate state medical specialty societies and physicians with expertise in the related field for their input. After all feedback is received from external reviews, it is presented for discussion at the next scheduled committee meeting. Based on feedback, subsequent guideline review, evaluation, and revision may be required prior to final guideline approval.&lt;/p&gt;&#xA;&lt;p&gt;The MQIC Medical Directors approved this guideline in March 2013.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The level of evidence grades (&lt;strong&gt;A-D&lt;/strong&gt;) are provided for the most significant recommendations and are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Periodic Assessment&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Assessment should include:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Height, weight, body mass index (BMI), blood pressure (BP) &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assess cardiovascular risks (smoking, hypertension, dyslipidemia, sedentary lifestyle, obesity, stress, family history, age &amp;gt;40 years) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Comprehensive foot exam (visual, monofilament, and pulses) &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Screen for depression &lt;strong&gt;[D]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dilated eye exam by ophthalmologist or optometrist &lt;strong&gt;[B]&lt;/strong&gt;, or if no prior retinopathy, may screen with fundal photography &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Frequency&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Perform periodic assessment at least annually &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Record BP at every visit &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In the absence of retinopathy repeat retinal eye exam in 2 years &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Laboratory Tests&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Tests should include:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A1C &lt;strong&gt;[D]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Urine microalbumin measurement &lt;strong&gt;[D]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Serum creatinine and calculated glomerular filtration rate (GFR) &lt;strong&gt;[D]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fasting lipid profile &lt;strong&gt;[D]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider thyroid-stimulating hormone (TSH) and liver function tests (LFTs) &lt;strong&gt;[D]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Frequency&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A1C: 2 - 4 times annually based on individual therapeutic goal; other tests at least annually&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Education, Counseling, and Risk Factor Modification&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Comprehensive diabetes self-management education (DSME) from a collaborative team or diabetic educator if available &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Education should be individualized, based on the National Standards for DSME&lt;sup&gt;1&lt;/sup&gt; &lt;strong&gt;[B]&lt;/strong&gt; and include:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Importance of regular physical activity and a healthy diet &lt;strong&gt;[A]&lt;/strong&gt;, and working towards an appropriate BMI &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Assessment of patient knowledge, attitudes, self-management skills and health status; strategies for making health behavior changes and addressing psychosocial concerns &lt;strong&gt;[C]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Description of diabetes disease process and treatment; safe and effective use of medications; prevention, detection and treatment of acute and chronic complications, including recognition of hypoglycemia &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Importance of nutrition management and regular physical activity &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Role of self-monitoring of blood glucose in glycemic control &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Cardiovascular risk reduction &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Smoking cessation intervention &lt;strong&gt;[B]&lt;/strong&gt; and secondhand smoke avoidance &lt;strong&gt;[C]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Self-care of feet &lt;strong&gt;[B]&lt;/strong&gt;; preconception counseling &lt;strong&gt;[D]&lt;/strong&gt;; encourage patients to receive dental care &lt;strong&gt;[D]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Frequency&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;At diagnosis and as needed&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Medical Recommendations&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Care should focus on smoking, hypertension, lipids, and glycemic control:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Medications for tobacco dependence unless contraindicated &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of hypertension using up to 3 - 4 anti-hypertensive medications to achieve adult target of &amp;lt;140/80 mm Hg &lt;strong&gt;[A]&lt;/strong&gt;. Mortality increases if diastolic is &amp;lt;70. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prescription of angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker in patients with hypertension or albuminuria &lt;strong&gt;[A]&lt;/strong&gt;&lt;sup&gt;2&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Statin therapy for primary prevention against macrovascular complications in patients with diabetes who have a low-density lipoprotein cholesterol (LDL-C) &amp;ge;100 or age &amp;ge;40 with another cardiovascular risk factor &lt;strong&gt;[A]&lt;/strong&gt;&lt;sup&gt;3&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Anti-platelet therapy &lt;strong&gt;[A]&lt;/strong&gt;: low dose aspirin for adults with cardiovascular disease (CVD) unless contraindicated. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Individualize the hemoglobin A1C&lt;sup&gt;4&lt;/sup&gt; goal&lt;sup&gt;5&lt;/sup&gt;. Goal for most patients is 7% to 8%. Mortality increases when A1C is &amp;gt;9% &lt;strong&gt;[B]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assurance of appropriate immunization status (tetanus, diphtheria, and acellular pertussis [Tdap] or tetanus-diphtheria [Td], influenza; pneumococcal vaccine, hepatitis B [Hep B]) &lt;strong&gt;[C]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;See &lt;a href=&quot;http://care.diabetesjournals.org/content/31/Supplement_1&quot; title=&quot;Diabetes Care Journal Web site&quot;&gt;http://care.diabetesjournals.org/content/vol31/Supplement_1/&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Consider referral of patients with serum creatinine value &amp;gt;2.0 mg/dL (adult value) or persistent albuminuria to nephrologist for evaluation.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Target LDL-C &amp;lt;100 mg/dL &lt;strong&gt;[B]&lt;/strong&gt;. For patients with overt CVD, a lower LDL-C goal of &amp;lt;70 mg/dL is an option &lt;strong&gt;[B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;A1C 6% = 126 eAG; estimated Average Glucose calculator &lt;a href=&quot;http://professional.diabetes.org/GlucoseCalculator.aspx&quot; title=&quot;Diabetes Pro Web site&quot;&gt;http://professional.diabetes.org/GlucoseCalculator.aspx&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Diabetes Care, Volume 36, Supplement 1, January 2013, S18:21, Table 9; &lt;a href=&quot;http://care.diabetesjournals.org/content/36/Supplement_1/S11.full.pdf+html&quot; title=&quot;Diabetes Care Journal Web site&quot;&gt;http://care.diabetesjournals.org/content/36/Supplement_1/S11.full.pdf+html&lt;/a&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Frequency&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;At each visit until therapeutic goals are achieved&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Evidence for the Most Significant Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Randomized controlled trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlled trials, no randomization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Observational studies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Opinion of expert panel &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of evidence is provided for the most significant recommendations (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline is based on several sources, including the American Diabetes Association Clinical Practice Recommendations 2013 (&lt;a href=&quot;http://www.diabetes.org/&quot; title=&quot;ADA Web site&quot;&gt;www.diabetes.org&lt;/a&gt;).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Through a collaborative approach to developing and implementing common clinical practice guidelines and performance measures for management of diabetes mellitus, Michigan health plans will achieve consistent delivery of evidence-based services and better health outcomes. This approach also will augment the practice environment for physicians by reducing the administrative burdens imposed by compliance with diverse health plan guidelines and associated requirements.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline lists core management steps. Individual patient considerations and advances in medical science may supersede or modify these recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Approved Michigan Quality Improvement Consortium (MQIC) guidelines are disseminated through email, U.S. mail, and websites.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst prepares approved guidelines for distribution. Portable Document Format (PDF) versions of the guidelines are used for distribution.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst distributes approved guidelines to MQIC membership via email.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst submits request to Web site vendor to post approved guidelines to the &lt;a href=&quot;http://www.mqic.org/&quot; title=&quot;MQIC Web site&quot;&gt;MQIC Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst completes an annual statewide postcard mailing to physicians in all areas of medicine including primary care and specialties. The postcard provides the complete list of MQIC guidelines and includes which guidelines have been recently revised, which are coming up for revision, and any new published guidelines.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The statewide mailing list is derived from the Blue Cross Blue Shield of Michigan (BCBSM) provider database. Approximately 95% of the state's M.D.'s and 96% of the state's D.O.'s are included in the database.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst submits request to the National Guideline Clearinghouse (NGC) to post approved guidelines to the &lt;a href=&quot;http://www.guideline.gov&quot; title=&quot;NGC Web site&quot; target=&quot;_blank&quot;&gt;NGC Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Chart Documentation/Checklists/Forms" /><FieldValue Value="Resources" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Michigan Quality Improvement Consortium. Management of diabetes mellitus. Southfield (MI): Michigan Quality Improvement Consortium; 2013 Mar. 1 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline is based on several sources, including the American Diabetes Association Clinical Practice Recommendations 2013 (&lt;a href=&quot;http://www.diabetes.org/&quot; title=&quot;ADA Web site&quot;&gt;www.diabetes.org&lt;/a&gt;).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2004 Jul (revised 2013 Mar)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Michigan Quality Improvement Consortium - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Michigan Quality Improvement Consortium&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Michigan Quality Improvement Consortium Medical Directors' Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Physician representatives from the 13 participating Michigan Quality Improvement Consortium health plans, Michigan State Medical Society, Michigan Osteopathic Association, Michigan Association of Health Plans, Michigan Department of Community Health, Michigan Peer Review Organization, and the University of Michigan Health System&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Standard disclosure is requested from all individuals participating in the Michigan Quality Improvement Consortium (MQIC) guideline development process, including those parties who are solicited for guideline feedback (e.g., health plans, medical specialty societies). Additionally, members of the MQIC Medical Directors' Committee are asked to disclose all commercial relationships as well.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Michigan Quality Improvement Consortium. Management of diabetes mellitus. Southfield (MI): Michigan Quality Improvement Consortium; 2012 Jun. 1 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.mqic.org/pdf/mqic_management_of_diabetes_mellitus_cpg.pdf&quot; title=&quot;Michigan Quality Improvement Consortium Web site&quot;&gt;Michigan Quality Improvement Consortium Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Diabetes mellitus patient checklist. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.mqic.com/physician-tools.htm&quot; title=&quot;MQIC Web site&quot;&gt;Michigan Quality Improvement Consortium (MQIC) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Blue Cross Blue Shield of Michigan good health club physician guidelines: prevention and treatment of pediatric obesity and diabetes. Available from the &lt;a href=&quot;http://www.mqic.com/physician-tools.htm&quot; title=&quot;MQIC Web site&quot;&gt;MQIC Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on December 10, 2004. The information was verified by the guideline developer on January 21, 2005. This NGC summary was updated by ECRI on October 13, 2006. The updated information was verified by the guideline developer on November 3, 2006. This NGC summary was updated by ECRI Institute on December 15, 2008. The updated information was verified by the guideline developer on December 17, 2008. This NGC summary was updated by ECRI Institute on January 18, 2011. The updated information was verified by the guideline developer on February 14, 2011. This summary was updated by ECRI Institute on June 27, 2011 following the U.S. Food and Drug Administration advisory on Zocor (simvastatin). This summary was updated by ECRI Institute on April 13, 2012 following the U.S. Food and Drug Administration advisories on Statin Drugs and Statins and HIV or Hepatitis C drugs. This NGC summary was updated by ECRI Institute on January 4, 2013. The updated information was verified by the guideline developer on February 7, 2013. This NGC summary was updated by ECRI Institute on August 22, 2013. The updated information was verified by the guideline developer on October 2, 2013.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which may be reproduced with the citation developed by the Michigan Quality Improvement Consortium.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
